A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
-
REGULATORY Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
-
REGULATORY Japan Seeks Additional Study for Aducanumab, Next Review Might Be Few Years Off
December 23, 2021
-
REGULATORY Gist of FY2022 Drug Pricing Reform
December 22, 2021
-
REGULATORY Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
-
COMMENTARY Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
-
BUSINESS Astellas to Abolish Pay Structure for Sales Reps, Switching to Company-Wide System Next April
December 20, 2021
-
BUSINESS Pfizer Agrees to Supply Oral COVID-19 Drugs for 2 Million People in Japan
December 20, 2021
-
BUSINESS Biogen to Challenge European Rejection of Aducanumab
December 20, 2021
-
BUSINESS Moderna to Develop All Global Pipeline Assets in Japan without Delay: Local Chief
December 17, 2021
-
BUSINESS Shionogi Pharma Eyes 10 Billion Yen Sales in CDMO Business in FY2022
December 17, 2021
-
REGULATORY Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
-
REGULATORY Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
-
REGULATORY Aducanumab Up for Japan Advisory Panel Review on December 22
December 15, 2021
-
REGULATORY MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
-
BUSINESS Chugai Files Actemra for COVID-19 Pneumonia in Japan
December 14, 2021
-
REGULATORY METI to Dole Out Support for “Dual-Use” Production Bases to Boost Pandemic Preparedness
December 13, 2021
-
REGULATORY Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
-
REGULATORY E Keppra Generics from 12 Firms to Join NHI Price List, Patanol and Velcade AGs Too
December 9, 2021
-
ACADEMIA With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…